{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:08:04Z","timestamp":1783897684577,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["CPP2022-009831"],"award-info":[{"award-number":["CPP2022-009831"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PTQ2021-011972"],"award-info":[{"award-number":["PTQ2021-011972"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013941","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Diabetes y Enfermedades Metab\u00f3licas Asociadas","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100013941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low plasma sex hormone\u2013binding globulin (SHBG) levels are commonly observed in metabolic dysfunction\u2013associated fatty liver disease (MASLD), a spectrum of disorders ranging from simple hepatocellular steatosis to steatohepatitis, fibrosis, and irreversible cirrhosis. We have previously demonstrated that SHBG overexpression reduces hepatic lipid accumulation by inhibiting lipogenesis both in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the present proof-of-concept study, we have developed a bioactive peptide that phenocopies SHBG-associated metabolic effects (EDL6D) and have evaluated its ability to inhibit lipogenesis in vitro using HepG2 cells treated daily with 30 mM fructose. In addition, we assessed the preventive and therapeutic effects of EDL6D in vivo in wild-type mice with MASLD induced by a high-fat diet combined with 30% fructose in drinking water.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment with EDL6D exerted both preventive and therapeutic effects, significantly reducing hepatic fat accumulation and promoting regression of MASLD compared with vehicle-treated mice. Mechanistically, EDL6D downregulated the mRNA expression and protein levels of key lipogenic enzymes, including ATP-citrate lyase, acetyl-CoA carboxylase, and fatty acid synthase, as well as peroxisome proliferator\u2013activated receptor gamma, a central lipogenic transcription factor. Notably, EDL6D prevented the development of mild fibrosis by reducing the expression of collagen type I alpha 1 chain (Col1a1) and transforming growth factor beta 1 (TGF-\u03b21).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MASLD remains as an unmet medical need and disease progression to fibrosis represents a major clinical challenge. This study identifies EDL6D as a novel preclinical lead compound that targets both hepatic lipid accumulation and suggests an antifibrotic effect. These findings support the translational potential of bioactive peptides phenocopying SHBG for the treatment and prevention of MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08305-9","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:14:34Z","timestamp":1778926474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: a new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Anna","family":"Alvarez-Guaita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Cabrera-Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Perez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Salcedo-Allende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Fuertes-Rioja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Ramos-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0333-5629","authenticated-orcid":false,"given":"David M.","family":"Selva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"8305_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.annepidem.2007.05.013","volume":"17","author":"LA Adams","year":"2007","unstructured":"Adams LA, Lindor KD. Nonalcoholic Fatty Liver Disease. Ann Epidemiol. 2007;17:863\u20139. https:\/\/doi.org\/10.1016\/j.annepidem.2007.05.013.","journal-title":"Ann Epidemiol"},{"key":"8305_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","volume":"5","author":"DG Tiniakos","year":"2010","unstructured":"Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis. Annu Rev Pathol. 2010;5:145\u201371. https:\/\/doi.org\/10.1146\/annurev-pathol-121808-102132.","journal-title":"Annu Rev Pathol"},{"key":"8305_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non\u2010alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274\u201385. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04724.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"8305_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"W-K Chan","year":"2023","unstructured":"Chan W-K, Chuah K-H, Rajaram RB, Lim L-L, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023;32:197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052.","journal-title":"J Obes Metab Syndr"},{"key":"8305_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.7861\/clinmedicine.11-2-176","volume":"11","author":"HC Thomas","year":"2011","unstructured":"Thomas HC, Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med. 2011;11:176\u20138. https:\/\/doi.org\/10.7861\/clinmedicine.11-2-176.","journal-title":"Clin Med"},{"issue":"2","key":"8305_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review. JAMA. 2026;335(2):163\u201374. https:\/\/doi.org\/10.1001\/jama.2025.19615.","journal-title":"JAMA"},{"key":"8305_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/cen.12360","volume":"80","author":"X Hua","year":"2014","unstructured":"Hua X, Sun Y, Zhong Y, Feng W, Huang H, Wang W, et al. Low serum sex hormone-binding globulin is associated with non-alcoholic fatty liver disease in type 2 diabetic patients. Clin Endocrinol (Oxf). 2014;80:877\u201383. https:\/\/doi.org\/10.1111\/cen.12360.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"8305_CR8","doi-asserted-by":"publisher","unstructured":"Siiteri PK, Murai JT, Raymoure WJ, Kuhn RW, Hammond GL, Nisker JA. The serum transport of steroid hormones. In: Proceedings of the 1981 Laurentian Hormone Conference. Elsevier; 1982. pp. 457\u2013510. https:\/\/doi.org\/10.1016\/B978-0-12-571138-8.50016-0.","DOI":"10.1016\/B978-0-12-571138-8.50016-0"},{"key":"8305_CR9","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1172\/JCI32249","volume":"117","author":"DM Selva","year":"2007","unstructured":"Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest. 2007;117:3979\u201387. https:\/\/doi.org\/10.1172\/JCI32249.","journal-title":"J Clin Invest"},{"key":"8305_CR10","doi-asserted-by":"publisher","first-page":"34105","DOI":"10.1074\/jbc.273.51.34105","volume":"273","author":"M J\u00e4nne","year":"1998","unstructured":"J\u00e4nne M, Hammond GL. Hepatocyte nuclear factor-4 controls transcription from a TATA-less human sex hormone-binding globulin gene promoter. J Biol Chem. 1998;273:34105\u201314. https:\/\/doi.org\/10.1074\/jbc.273.51.34105.","journal-title":"J Biol Chem"},{"key":"8305_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/db11-0727","volume":"61","author":"R Sim\u00f3","year":"2012","unstructured":"Sim\u00f3 R, Barbosa-Desongles A, Lecube A, Hernandez C, Selva DM. Potential role of tumor necrosis factor-\u03b1 in downregulating sex hormone-binding globulin. Diabetes. 2012;61:372\u201382. https:\/\/doi.org\/10.2337\/db11-0727.","journal-title":"Diabetes"},{"key":"8305_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1210\/me.2011-1321","volume":"26","author":"R Sim\u00f3","year":"2012","unstructured":"Sim\u00f3 R, Barbosa-Desongles A, S\u00e1ez-Lopez C, Lecube A, Hernandez C, Selva DM. Molecular Mechanism of TNF\u03b1-Induced Down-Regulation of SHBG Expression. Mol Endocrinol. 2012;26:438\u201346. https:\/\/doi.org\/10.1210\/me.2011-1321.","journal-title":"Mol Endocrinol"},{"key":"8305_CR13","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1210\/me.2012-1152","volume":"26","author":"R Sim\u00f3","year":"2012","unstructured":"Sim\u00f3 R, Barbosa-Desongles A, Hernandez C, Selva DM. IL1\u03b2 down-regulation of sex hormone-binding globulin production by decreasing HNF-4\u03b1 via MEK-1\/2 and JNK MAPK pathways. Mol Endocrinol. 2012;26:1917\u201327. https:\/\/doi.org\/10.1210\/me.2012-1152.","journal-title":"Mol Endocrinol"},{"key":"8305_CR14","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1210\/en.2014-1072","volume":"155","author":"R Sim\u00f3","year":"2014","unstructured":"Sim\u00f3 R, Saez-Lopez C, Lecube A, Hernandez C, Fort JM, Selva DM. Adiponectin upregulates SHBG production: Molecular mechanisms and potential implications. Endocrinol Endocr Soc. 2014;155:2820\u201330. https:\/\/doi.org\/10.1210\/en.2014-1072.","journal-title":"Endocrinol Endocr Soc"},{"key":"8305_CR15","doi-asserted-by":"publisher","unstructured":"Sim\u00f3 R, S\u00e1ez-L\u00f3pez C, Barbosa-Desongles A, Hern\u00e1ndez C, Selva DM. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab. Elsevier Inc.; 2015. pp. 376\u201383. https:\/\/doi.org\/10.1016\/j.tem.2015.05.001.","DOI":"10.1016\/j.tem.2015.05.001"},{"key":"8305_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209\u201318. https:\/\/doi.org\/10.1172\/JCI24282.","journal-title":"J Clin Invest"},{"key":"8305_CR17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/febs.13665","volume":"283","author":"I Fabregat","year":"2016","unstructured":"Fabregat I, Moreno-C\u00e0ceres J, S\u00e1nchez A, Dooley S, Dewidar B, Giannelli G, et al. TGF-\u03b2 signalling and liver disease. FEBS J. 2016;283:2219\u201332. https:\/\/doi.org\/10.1111\/febs.13665.","journal-title":"FEBS J"},{"key":"8305_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.26698","volume":"59","author":"L Yang","year":"2014","unstructured":"Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014;59:483\u201395. https:\/\/doi.org\/10.1002\/hep.26698.","journal-title":"Hepatology"},{"key":"8305_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","volume":"13","author":"E Seki","year":"2007","unstructured":"Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324\u201332. https:\/\/doi.org\/10.1038\/nm1663.","journal-title":"Nat Med"},{"key":"8305_CR20","doi-asserted-by":"publisher","first-page":"e20190103","DOI":"10.1084\/jem.20190103","volume":"217","author":"N Frangogiannis","year":"2020","unstructured":"Frangogiannis N. Transforming growth factor-\u03b2 in tissue fibrosis. J Exp Med. 2020;217:e20190103. https:\/\/doi.org\/10.1084\/jem.20190103.","journal-title":"J Exp Med"},{"key":"8305_CR21","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1053\/j.gastro.2006.01.042","volume":"130","author":"S Klein","year":"2006","unstructured":"Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology. 2006;130:1564\u201372. https:\/\/doi.org\/10.1053\/j.gastro.2006.01.042.","journal-title":"Gastroenterology"},{"key":"8305_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/j.1478-3231.2006.01337.x","volume":"26","author":"A Cay\u00f3n","year":"2006","unstructured":"Cay\u00f3n A, Crespo J, Mayorga M, Guerra A, Pons-Romero F. Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. Liver Int. 2006;26:1065\u201371. https:\/\/doi.org\/10.1111\/j.1478-3231.2006.01337.x.","journal-title":"Liver Int"},{"key":"8305_CR23","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1002\/jcp.30818","volume":"237","author":"L Brians\u00f3-Llort","year":"2022","unstructured":"Brians\u00f3-Llort L, Fuertes-Rioja L, Ramos-Perez L, Salcedo-Allende MT, Hernandez C, Sim\u00f3 R, et al. Transforming growth factor-beta 1: A new factor reducing hepatic SHBG production in liver fibrosis. J Cell Physiol. 2022;237:3598\u2013613. https:\/\/doi.org\/10.1002\/jcp.30818.","journal-title":"J Cell Physiol"},{"key":"8305_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1210\/en.2016-1668","volume":"158","author":"C Saez-Lopez","year":"2017","unstructured":"Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Dyer RA, Innis SM, Sim\u00f3 R, et al. Sex Hormone-Binding Globulin Reduction in Metabolic Disorders May Play a Role in NAFLD Development. Endocrinology. 2017;158:545\u201359. https:\/\/doi.org\/10.1210\/en.2016-1668.","journal-title":"Endocrinology"},{"key":"8305_CR25","doi-asserted-by":"publisher","first-page":"108908","DOI":"10.1016\/j.pharmthera.2025.108908","volume":"274","author":"A Eftekhari","year":"2025","unstructured":"Eftekhari A, Sabir U, Kasumov T. The role of lysine acetylation in metabolic sensing and proteostasis. Pharmacol Ther. 2025;274:108908. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108908.","journal-title":"Pharmacol Ther"},{"key":"8305_CR26","doi-asserted-by":"publisher","unstructured":"Evaluation of cytotoxic and antimicrobial activities of methanolic extracts from Cystoseira foeniculacea and Sargassum vulgare. Adv Biology Earth Sci. 2025;10. https:\/\/doi.org\/10.62476\/abes.102347.","DOI":"10.62476\/abes.102347"},{"key":"8305_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.62476\/abes.101111","volume":"10","author":"Drugs Loaded in Bilosomes for the Treatment of Gastrointestinal Cancers","year":"2025","unstructured":"Drugs Loaded in Bilosomes for the Treatment of Gastrointestinal Cancers. Compr Rev Adv Biology Earth Sci. 2025;10:111\u201334. https:\/\/doi.org\/10.62476\/abes.101111.","journal-title":"Compr Rev Adv Biology Earth Sci"},{"key":"8305_CR28","doi-asserted-by":"publisher","first-page":"18362","DOI":"10.1016\/S0021-9258(17)44760-0","volume":"265","author":"MS Khan","year":"1990","unstructured":"Khan MS, Hryb DJ, Hashim GA, Romas NA, Rosner W. Delineation and synthesis of the membrane receptor-binding domain of sex hormone-binding globulin. J Biol Chem. 1990;265:18362\u20135.","journal-title":"J Biol Chem"},{"key":"8305_CR29","doi-asserted-by":"publisher","unstructured":"Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-dysfunction-associated steatotic liver disease \u2013 its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms242015473.","DOI":"10.3390\/ijms242015473"},{"key":"8305_CR30","unstructured":"Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis."},{"key":"8305_CR31","doi-asserted-by":"publisher","first-page":"e2621","DOI":"10.1097\/MD.0000000000002621","volume":"95","author":"N Wang","year":"2016","unstructured":"Wang N, Zhai H, Zhu C, Li Q, Han B, Chen Y, et al. Combined Association of Vitamin D and Sex Hormone Binding Globulin With Nonalcoholic Fatty Liver Disease in Men and Postmenopausal Women. Medicine. 2016;95:e2621. https:\/\/doi.org\/10.1097\/MD.0000000000002621.","journal-title":"Medicine"},{"key":"8305_CR32","doi-asserted-by":"publisher","unstructured":"Wang X, Xie J, Pang J, Zhang H, Chen X, Lin J, et al. Serum SHBG is associated with the development and regression of nonalcoholic fatty liver disease: a prospective study. J Clin Endocrinol Metab. 2020;105. https:\/\/doi.org\/10.1210\/clinem\/dgz244.","DOI":"10.1210\/clinem\/dgz244"},{"key":"8305_CR33","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.cgh.2014.12.033","volume":"13","author":"M Lazo","year":"2015","unstructured":"Lazo M, Zeb I, Nasir K, Tracy RP, Budoff MJ, Ouyang P, et al. Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis. Clin Gastroenterol Hepatol. 2015;13:1686\u201393.e2. https:\/\/doi.org\/10.1016\/j.cgh.2014.12.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8305_CR34","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1210\/clinem\/dgaa574","volume":"105","author":"NT Mueller","year":"2020","unstructured":"Mueller NT, Liu T, Mitchel EB, Yates KP, Suzuki A, Behling C, et al. Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2020;105:3496\u2013504. https:\/\/doi.org\/10.1210\/clinem\/dgaa574.","journal-title":"J Clin Endocrinol Metab"},{"key":"8305_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1530\/EJE-09-0202","volume":"161","author":"F Bonnet","year":"2009","unstructured":"Bonnet F, Balkau B, Mal\u00e9cot JM, Picard P, Lange C, Fumeron F, et al. Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels. Eur J Endocrinol. 2009;161:81\u20135. https:\/\/doi.org\/10.1530\/EJE-09-0202.","journal-title":"Eur J Endocrinol"},{"key":"8305_CR36","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1056\/NEJMoa0804381","volume":"361","author":"EL Ding","year":"2009","unstructured":"Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, et al. Sex Hormone\u2013Binding Globulin and Risk of Type 2 Diabetes in Women and Men. N Engl J Med. 2009;361:1152\u201363. https:\/\/doi.org\/10.1056\/NEJMoa0804381.","journal-title":"N Engl J Med"},{"key":"8305_CR37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/01.atv.9.1.136","volume":"9","author":"SM Haffner","year":"1989","unstructured":"Haffner SM, Katz MS, Stern MP, Dunn JF. Association of decreased sex hormone binding globulin and cardiovascular risk factors. Arteriosclerosis. 1989;9:136\u201343. https:\/\/doi.org\/10.1161\/01.atv.9.1.136.","journal-title":"Arteriosclerosis"},{"key":"8305_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1210\/jc.2007-1738","volume":"93","author":"R Karim","year":"2008","unstructured":"Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2008;93:131\u20138. https:\/\/doi.org\/10.1210\/jc.2007-1738.","journal-title":"J Clin Endocrinol Metab"},{"key":"8305_CR39","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1161\/01.CIR.0000157697.54255.CE","volume":"111","author":"K Sutton-Tyrrell","year":"2005","unstructured":"Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, et al. Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation. 2005;111:1242\u20139. https:\/\/doi.org\/10.1161\/01.CIR.0000157697.54255.CE.","journal-title":"Circulation"},{"key":"8305_CR40","doi-asserted-by":"publisher","unstructured":"Saez-Lopez C, Villena JA, Sim\u00f3 R, Selva DM. Sex hormone-binding globulin overexpression protects against high-fat diet-induced obesity in transgenic male mice. J Nutr Biochem. Elsevier Inc.; 2020;85. https:\/\/doi.org\/10.1016\/j.jnutbio.2020.108480.","DOI":"10.1016\/j.jnutbio.2020.108480"},{"issue":"1","key":"8305_CR41","doi-asserted-by":"publisher","first-page":"e48425","DOI":"10.1371\/journal.pone.0048425","volume":"8","author":"MA Preethi Samuel","year":"2013","unstructured":"Preethi Samuel MA, Khan S, Nag T, Inagami. Tahir Hussain. Angiotensin AT(2) receptor contributes towards gender bias in weight gain. PLoS ONE. 2013;8(1):e48425. https:\/\/doi.org\/10.1371\/journal.pone.0048425.","journal-title":"PLoS ONE"},{"key":"8305_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.21006","volume":"43","author":"X Ding","year":"2006","unstructured":"442, Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice. Hepatology. 2006;43:173\u201381. https:\/\/doi.org\/10.1002\/hep.21006.","journal-title":"Hepatology"},{"key":"8305_CR43","doi-asserted-by":"publisher","first-page":"1046130","DOI":"10.3389\/fendo.2022.1046130","volume":"13","author":"S Niu","year":"2022","unstructured":"Niu S, Chen S, Chen X, Ren Q, Yue L, Pan X, et al. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front Endocrinol (Lausanne). 2022;13:1046130. https:\/\/doi.org\/10.3389\/fendo.2022.1046130.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8305_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41366-021-00955-7","volume":"46","author":"RM Pontes-da-Silva","year":"2022","unstructured":"Pontes-da-Silva RM, de Souza Marinho T, de Macedo Cardoso LE, Mandarim-de-Lacerda CA, Aguila MB. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist. Int J Obes (Lond). 2022;46:21\u20139. https:\/\/doi.org\/10.1038\/s41366-021-00955-7.","journal-title":"Int J Obes (Lond)"},{"key":"8305_CR45","doi-asserted-by":"publisher","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5. https:\/\/doi.org\/10.1172\/jci.insight.133429.","DOI":"10.1172\/jci.insight.133429"},{"key":"8305_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s44355-024-00004-w","volume":"1","author":"X-D 46 Zhou","year":"2024","unstructured":"46 Zhou X-D, Wong VW-S, Zheng M-H. Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive. npj Gut Liver. 2024;1:4. https:\/\/doi.org\/10.1038\/s44355-024-00004-w.","journal-title":"npj Gut Liver"},{"key":"8305_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0014-5793(01)02655-2","volume":"502","author":"M Bauer","year":"2001","unstructured":"Bauer M, Schuppan D. TGFbeta1 in liver fibrosis: time to change paradigms? FEBS Lett. 2001;502:1\u20133. https:\/\/doi.org\/10.1016\/s0014-5793(01)02655-2.","journal-title":"FEBS Lett"},{"key":"8305_CR48","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200005043421807","volume":"342","author":"GC Blobe","year":"2000","unstructured":"Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350\u20138. https:\/\/doi.org\/10.1056\/NEJM200005043421807.","journal-title":"N Engl J Med"},{"key":"8305_CR49","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","volume":"331","author":"WA Border","year":"1994","unstructured":"Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286\u201392. https:\/\/doi.org\/10.1056\/NEJM199411103311907.","journal-title":"N Engl J Med"},{"key":"8305_CR50","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"key":"8305_CR51","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023;29:562\u201373. https:\/\/doi.org\/10.1038\/s41591-023-02242-6.","journal-title":"Nat Med"},{"key":"8305_CR52","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(19)32517-6.","journal-title":"Lancet"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08305-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:00:14Z","timestamp":1783897214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08305-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8305"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08305-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental procedures were reviewed and approved by the Animal Experimentation Ethics Committee of the Vall d\u2019Hebron Research Institute (VHIR) and by the competent authority of the Generalitat de Catalunya, and were conducted in accordance with institutional guidelines, Spanish legislation (Real Decreto 53\/2013), and European Union Directive 2010\/63\/EU on the protection of animals used for scientific purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"DMS and RS are co-founders of Endolipid Therapeutics SL which is currently developing EDL6D for the treatment of MASLD and MASH. AAG and BPG are postdoctoral fellows of Endolipid Therapeutics SL, respectively. The rest of the authors declare they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"883"}}